Volv Global Poster: Early prediction of ARDS in community-acquired pneumonia patients using machine learning
Presenting new research on whether a machine learning model can flag which patients with CAP are most likely to progr...
In numbers
Special details
Gait and limb ataxia is the presenting feature in most patients, usually the first sign that prompts investigation.
Affects 60 to 80 percent of patients and is the leading cause of premature death.
Absent ankle reflexes and loss of vibration and joint-position sense reflect dorsal root ganglion degeneration.
Affects around 60 percent of patients, often progressing in adolescence and sometimes requiring spinal fusion.
Insulin-deficient diabetes develops in 10 to 30 percent of patients as pancreatic beta cells are affected.
The earliest pipeline decisions carry lasting consequences: the wrong indication chosen, indications pursued in the wrong order, or capital committed where expected returns already trail its cost. Mistakes made this early are expensive to correct later.
When patients cannot be found, recruitment stalls and the burn rate climbs. High screen-failure rates add further cost and delay, and a mixed cohort makes the results harder to interpret.
Finds the undiagnosed and mis-coded patients conventional feasibility misses, widening the recruitable pool.
Surfaces diagnosed-but-hidden, trial-eligible patients already in the data, so sites enrol faster.
Predicts who will progress or respond, enriching the cohort so the signal is not diluted.
Without strong, timely evidence, payers can restrict access or cut the price. An under-characterised population weakens the budget case, and HTA approval demands more evidence than regulatory approval alone.
Generates the real-world evidence and outcomes payers ask for, ahead of the submission deadline.
Finds the undiagnosed patients missing from the count, so the eligible population holds up under scrutiny.
Surfaces the diagnosed-but-eligible patients who expand the eligible population count.
Healthcare data is fragmented across markets, so evidence has to be rebuilt market by market, slowing decisions. Time to an accurate diagnosis varies by who the patient is and where they are treated.
Works across fragmented, differently-coded data by design, so insight holds up country to country without a rebuild.
Detects patients ahead of typical diagnosis, closing the gap in awareness and pathway that drives unequal delay.
A launch planned without a view of findable patients is poorly resourced from day one. Targeting too broad a population slows early uptake, and real-world evidence gathered too late leaves little time to build a strong access dossier.
Finds the treatable patients, so the launch is planned against real demand.
Adds the eligible, reachable patients that launch planning is missing.
Builds the access evidence early enough to matter.
No posts found.
Presenting new research on whether a machine learning model can flag which patients with CAP are most likely to progr...
Results for the model flagging early ARDS risk in pneumonia will be presented at ERS Congress 2026.
Volv Global joins Innovaud, One Nucleus & ARC West London to explore innovation and investment opportunities acro...
Volv Global at ERS Congress 2026, presenting new research in collaboration with CSL Behring: Can We Catch ARDS Before...
AI Innovation in Real-World Evidence & Data Analytics Volv Global has been selected as a finalist in the 2026 Fie...
Volv Global applied machine learning to 24M UK primary care records, surfacing ~1,200 undiagnosed GEP-NET patients, 5...
ASCO 2026 produced landmark oncology data. The question no one asked from the podium: can clinical infrastructure get...
Drive For Change white paper: three paradigm shifts to unlock orphan drug development
Approximately 95% of rare diseases have no approved treatment. Drive For Change identifies three structural paradigms...
Machine learning applied to 3,549 confirmed Pompe disease patients – the largest machine learning study of the diseas...
New research demonstrates that machine learning can map clinician-defined endpoints to real-world claims data in Pomp...
Volv Global joins Tech Tour Growth Health 2026 in Lausanne, 30 June – 1 July, connecting with Europe's leading health...